Elimination of Graft Versus Host Disease in Matched Allogeneic Leukemic Transplant Recipients Using Campath-1
Bone marrow transplantation (BMT) offers one of the major advances in the treatment of certain malignant hematological disorders for which no specific effective alternative therapeutic modality exists, particularly leukemias. Although results of BMT in man have improved over the last few years, success rates have been limited mainly due to the reactivity of the graft against the host, a disease called graft versus host disease (GVHD). None of the treatment modalities studied thus far seems to be effective against established GVHD. Therefore, it appears that prevention of GVHD is the best approach to overcome the obstacle of GVHD. Since experimental data and recent pilot clinical studies suggest that acute GVHD results from donor type mature T cells present in the marrow aspirate (1–9), it would seem that the safest way to prevent GVHD is by elimination of T cells from the marrow allograft prior to transplantation. The present report summarizes our initial results in trying to prevent GVHD in patients undergoing BMT for leukemia using a monoclonal anti-lymphocyte antibody, CAMPATH-1 (10). Two major advantages of this novel antibody are: 1) its ability to deplete all lymphoid cells, including T cells, without damaging the stem cell compartment; and, 2) the unique characteristic of this antibody to bind human complement.
KeywordsMagnesium Albumin Leukemia Penicillin Methotrexate
Unable to display preview. Download preview PDF.
- 3.H. V. Rodt, S. Thierfelder, and M. Eulitz, Anti-lymphocytic antibodies and marrow transplantation. Ill Effect of heterologous anti-brain antibodies on acute secondary disease in mice, Eur. J. Immunol. 4: 25 (1974).Google Scholar
- 7.R. Korngold, and J. Sprent, Surface markers of T cells causing lethal graft-versus-host disease in mice, in“Recent Advances in Bone Marrow Transplantation,” R. P. Gale, ed., Alan R. Liss, New York (1983).Google Scholar